Technology
Health
Biotechnology

ContraFect

$0.4899
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0059 (1.22%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, ETFs, and crypto commission-free!

About

ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. Read More The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Employees
20
Headquarters
Yonkers, New York
Founded
2008
Market Cap
38.90M
Price-Earnings Ratio
Dividend Yield
Average Volume
577.46K
High Today
$0.4975
Low Today
$0.4751
Open Price
$0.4905
Volume
143.01K
52 Week High
$2.93
52 Week Low
$0.355

Collections

Technology
Health
Biotechnology
Medical
2014 IPO
US
North America

News

NasdaqMay 8

ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease

ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease Presentations to include new data from the Phase 2 superiority design trial of exebacase for the treatment of Staph aureus bacteremia, including endocarditis YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistan...

200
Yahoo FinanceApr 30

CFRX: Additional Phase 2 Data Presented at ECCMID…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Additional Data Presented for Exebacase Phase 2 Trial On April 16, 2019, Contrafect Corp. (CFRX) announced the presentation of new data from the Phase 2 clinical trial of exebacase (CF-301) for the treatment of Staphylococcus aureus bacteremia including endocarditis at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data was presented by Vance G. Fowler, Jr., M.D., Prof...

462

Earnings

-$0.27
-$0.19
-$0.10
-$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.10 per share
Actual
-$0.08 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.